Iovance Biotherapeutics Inc (IOVA)

$1.82 +0.06 (3.41%)
Market Cap 584.39M
Revenue (ttm) 164.07M
Net Income (ttm) -372.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -226.84%
Debt to Equity Ratio 0.00
Volume 9,883,101
Avg Vol 13,509,472
Day's Range N/A - N/A
Shares Out 333.93M
Stochastic %K 30%
Beta 1.06
Analysts Strong Sell
Price Target $10.70

Latest News on IOVA

IOVA STOCK NOTICE: Iovance Biotherapeutics, Inc. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 14 Legal Deadline

Jun 3, 2025, 3:33 PM EDT - 20 hours ago

IOVA STOCK NOTICE: Iovance Biotherapeutics, Inc. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 14 Legal Deadline

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Jun 2, 2025, 10:06 AM EDT - 2 days ago

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma

Jun 2, 2025, 9:29 AM EDT - 2 days ago

The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma

IOVA CLASS NOTICE: Iovance Biotherapeutics, Inc. Investors may have been Affected by Fraud – Contact BFA Law before July 14 Court Deadline (NASDAQ:IOVA)

May 31, 2025, 7:08 AM EDT - 4 days ago

IOVA CLASS NOTICE: Iovance Biotherapeutics, Inc. Investors may have been Affected by Fraud – Contact BFA Law before July 14 Court Deadline (NASDAQ:IOVA)

Scott+Scott Attorneys at Law LLP Continues to Remind Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

May 29, 2025, 12:03 PM EDT - 6 days ago

Scott+Scott Attorneys at Law LLP Continues to Remind Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

IOVA FRAUD: Suffer Losses on Iovance Biotherapeutics, Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:IOVA)

May 25, 2025, 7:42 AM EDT - 10 days ago

IOVA FRAUD: Suffer Losses on Iovance Biotherapeutics, Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:IOVA)

IOVA FRAUD NEWS: Iovance Biotherapeutics, Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by July 14 Court Deadline

May 23, 2025, 3:18 PM EDT - 11 days ago

IOVA FRAUD NEWS: Iovance Biotherapeutics, Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by July 14 Court Deadline

Scott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Action Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

May 23, 2025, 12:03 PM EDT - 12 days ago

Scott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Action Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

May 22, 2025, 5:31 PM EDT - 12 days ago

Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

May 21, 2025, 1:23 PM EDT - 13 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

Scott+Scott Attorneys at Law LLP Alerts Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

May 21, 2025, 12:01 PM EDT - 14 days ago

Scott+Scott Attorneys at Law LLP Alerts Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

IOVA LAWSUIT: Lose Money on Iovance Biotherapeutics, Inc.? Contact BFA Law before July 14 Court Deadline

May 21, 2025, 8:42 AM EDT - 14 days ago

IOVA LAWSUIT: Lose Money on Iovance Biotherapeutics, Inc.? Contact BFA Law before July 14 Court Deadline

Iovance Shareholders Should Contact Shareholder Rights Firm Regarding Potential Legal Claims

May 17, 2025, 8:00 AM EDT - 18 days ago

Iovance Shareholders Should Contact Shareholder Rights Firm Regarding Potential Legal Claims

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025, 5:30 PM EDT - 18 days ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Reach Out

May 16, 2025, 10:00 AM EDT - 19 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Reach Out

Lovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman

May 15, 2025, 2:30 PM EDT - 19 days ago

Lovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman

Iovance Biotherapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - IOVA

May 15, 2025, 12:10 PM EDT - 20 days ago

Iovance Biotherapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - IOVA

Bronstein, Gewirtz & Grossman, LLC Is Investigating Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Connect

May 15, 2025, 10:00 AM EDT - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Connect

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman

May 14, 2025, 4:47 PM EDT - 20 days ago

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 14, 2025, 10:00 AM EDT - 21 days ago

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Iovance Biotherapeutics, Inc. (IOVA) and Encourages Stockholders to Learn More About the Investigation

May 13, 2025, 10:00 AM EDT - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Iovance Biotherapeutics, Inc. (IOVA) and Encourages Stockholders to Learn More About the Investigation

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman

May 13, 2025, 9:00 AM EDT - 22 days ago

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman

Bronstein, Gewirtz & Grossman, LLC Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors to Inquire about Securities Investigation

May 12, 2025, 4:00 PM EDT - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors to Inquire about Securities Investigation

Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity

May 12, 2025, 1:28 AM EDT - 23 days ago

Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity